The U.S. Food and Drug Administration has approved a new once-daily HIV treatment from Gilead Sciences called Bixlenvo, offering a simplified treatment option for some adults living with HIV.
The medication is designed for patients whose HIV is already controlled but who cannot use currently available single-tablet treatments due to drug resistance, side effects, or other medical considerations. It may also provide an alternative option for people who want to switch from their current treatment.
New Treatment Combines Two HIV Medicines
Bixlenvo combines bictegravir, the active component of Gilead’s widely used HIV medication Biktarvy, with lenacapavir, a newer capsid inhibitor that has become a key part of Gilead’s long-term HIV treatment and prevention strategy.
According to Gilead, the approval makes Bixlenvo the first single-tablet regimen available for adults with suppressed HIV who are unable to use existing one-pill treatment options. The company estimates this group represents at least 5% of people living with HIV in the United States.
Expanding Options for People Living With HIV
While many people with HIV can manage the condition with one daily pill, some patients require more complex treatment plans. Factors such as resistance from older therapies, medication interactions, or side effects can make existing treatments unsuitable.
These patients may need multiple medications and complicated schedules. Dr. Jared Baeten, Gilead’s clinical development and virology therapeutic area head, said Bixlenvo addresses an unmet need by helping some patients consolidate their treatment into a simpler daily regimen.
The treatment may be particularly meaningful for older adults who have lived with HIV for decades and have experienced multiple treatment changes throughout their lives.
Bixlenvo Is Not a Replacement for Biktarvy
Gilead emphasized that Bixlenvo is not intended to replace Biktarvy. Instead, the company sees it as another option within a broader strategy to give patients more flexibility in choosing treatments that fit their health needs and lifestyle.
The company is developing a wider range of HIV treatment options based on lenacapavir, including daily pills, weekly oral treatments, and longer-acting injectable therapies.
Clinical Trial Results Support Approval
The FDA approval was supported by two Phase 3 clinical trials involving adults with suppressed HIV who either switched from Biktarvy or moved away from more complex multi-pill treatment plans.
In the studies, Bixlenvo maintained viral suppression at rates comparable to previous treatments after 48 weeks. The medication was generally well tolerated, with commonly reported side effects including headache, nausea, and diarrhea.
One participant, Timothy Cameron, a retired Seattle resident who has lived with HIV for more than 40 years, said the once-daily pill simplified his treatment routine after years of managing complex medication combinations and drug resistance.
Cost and Patient Assistance Programs
The list price for Bixlenvo is $4,595 for a 30-day supply before discounts or rebates, according to Gilead. The company said uninsured patients may qualify for free access through its patient assistance program, while eligible privately insured patients may receive financial support through savings programs.
Future of HIV Treatment
Although there is currently no cure for HIV, modern treatments allow many people to control the virus and maintain long-term health. Bixlenvo represents another step toward more personalized HIV care by expanding the number of available treatment options.
Gilead said its goal is to provide enough flexibility for patients and healthcare providers to choose treatment approaches that best support long-term disease management.
